Ex Parte DIMARCHI et al - Page 19






              Appeal No. 2004-0250                                                              Page 19                
              Application No. 09/226,412                                                                               

                                                       Table 3                                                         

               Claims 31 and 32 directed to delivering      The method of Rubsamen provides for                        
               the monomeric insulin analog to a lower      delivery of the active agent to the lungs                  
               airway of the patient, e.g., the alveoli.    of the patient.  Id., column 17, lines 6-10.               
                                                            In view of this disclosure it is reasonable                
                                                            to shift the burden to appellants to                       
                                                            establish through objective evidence that                  
                                                            the method described in Rubsamen does                      
                                                            not deliver the insulin to the lower airway                
                                                            of the patient, e.g., the alveoli.  In re                  
                                                            Best, 562 F.2d 1252, 1255, 195 USPQ                        
                                                            430, 433 (CCPA 1977).                                      
               Claims 34-37 and 42-44 directed to           Rubsamen describes administering a                         
               formulating the monomeric insulin analog     monomeric insulin analog in the form of                    
               with a pharmaceutical carrier, including     an aerosol containing the active agent in                  
               suspending the active agent in a non-        the form of a powder with or without a                     
               aqueous medium, administering the            non-aqueous propellant using an                            
               active agent in the form of an aerosol       inhalation device.  See column 14, line                    
               and/or a dry powder, using an inhalation     40-column 15, line 30 and column 20,                       
               device such as a metered dose inhaler or     line 62-column 21, line 9.                                 
               a dry powder inhaler.                                                                                   
               Claims 38-40 directed the particle size of   The monomeric insulin analog of                            
               the monomeric insulin analog.                Rubsamen is used in the form of a                          
                                                            powder.  As such, it would have been                       
                                                            obvious to optimize the particle size of                   
                                                            the powder as this is a result effective                   
                                                            variable.  In re Boesch, 617 F.2d 272,                     
                                                            276, 205 USPQ 215, 219 (CCPA 1980).                        
               Claims 45-46 directed the amount of          Rubsamen, column 5, lines 55-68  In                        
               monomeric insulin analog to be               view of this disclosure it is reasonable to                
               administered.                                shift the burden to appellants to establish                
                                                            through objective evidence that the                        
                                                            amounts of the insulin analog delivered in                 
                                                            Rubsamen do not meet those required by                     
                                                            these claims.  In re Best, 562 F.2d 1252,                  
                                                            1255, 195 USPQ 430, 433 (CCPA 1977).                       






Page:  Previous  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  Next 

Last modified: November 3, 2007